Key Takeaways Cagrilintide is a long-acting amylin analogue typically dosed at 2.4 mg weekly in clinical trials, working through distinct pathways from GLP-1 receptor agonists Tirzepatide follows a gradual escalation protocol from 2.5 mg to 15 mg weekly as a dual GIP/GLP-1 receptor agonist No approved combination of cagrilintide with tirzepatide currently exists, though the concept represents theoretical triple-pathway metabolic modulation Gastrointestinal side effects require careful monitoring when considering any combination of these peptides due to overlapping mechanisms Clinical evidence for cagrilintide combinations exists primarily with semaglutide, showing 15-17% body weight reductions in phase 3 trials Understanding Cagrilintide: The Amylin Analogue Cagrilintide represents a breakthrough in amylin-based therapeutics, developed by Novo Nordisk as a long-acting analogue of the naturally occurring hormone amylin[1]
Can genetic testing help me understand my response to semaglutide
GLP-1 medications have shown promise in slowing the progression of kidney damage
Eggersdorfer, M., & Wyss, A
This leads to a reduction in fine lines, wrinkles, and other signs of aging
Inconsistent mealtimes can also impact your blood sugars negatively, as when you wait too long to eat, your bodys natural response is to secrete glucose (stored sugar) from your liver in order to prevent drops in blood sugar
